Literature DB >> 17497245

Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.

O El-Kabbani1, A Podjarny.   

Abstract

Aldose reductase and aldehyde reductase belong to the aldo-keto reductase superfamily of enzymes whose members are responsible for a wide variety of biological functions. Aldose reductase has been identified as the first enzyme involved in the polyol pathway of glucose metabolism which converts glucose into sorbitol. Glucose over-utilization through the polyol pathway has been linked to tissue-based pathologies associated with diabetes complications, which make the development of a potent aldose reductase inhibitor an obvious and attractive strategy to prevent or delay the onset and progression of the complications. Structural studies of aldose reductase and the homologous aldehyde reductase in complex with inhibitor were carried out to explain the difference in the potency of enzyme inhibition. The aim of this review is to provide a comprehensive summary of previous studies to aid the development of aldose reductase inhibitors that may have less toxicity problems than the currently available ones.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497245     DOI: 10.1007/s00018-007-6514-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  12 in total

Review 1.  A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases.

Authors:  Saumya Pandey; Satish K Srivastava; Kota V Ramana
Journal:  Expert Opin Investig Drugs       Date:  2012-01-28       Impact factor: 6.206

2.  Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a.

Authors:  Ashish Saxena; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Antioxid Redox Signal       Date:  2012-10-25       Impact factor: 8.401

3.  Crystal packing modifies ligand binding affinity: the case of aldose reductase.

Authors:  Alexandra Cousido-Siah; Tatiana Petrova; Isabelle Hazemann; André Mitschler; Francesc X Ruiz; Eduardo Howard; Stephan Ginell; Cédric Atmanene; Alain Van Dorsselaer; Sarah Sanglier-Cianférani; Andrzej Joachimiak; Alberto Podjarny
Journal:  Proteins       Date:  2012-07-28

4.  Structural and biochemical analyses of YvgN and YtbE from Bacillus subtilis.

Authors:  Jian Lei; Yan-Feng Zhou; Lan-Fen Li; Xiao-Dong Su
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

5.  Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract.

Authors:  Milan Stefek
Journal:  Interdiscip Toxicol       Date:  2011-06

6.  Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.

Authors:  F Xavier Ruiz; Sergio Porté; Xavier Parés; Jaume Farrés
Journal:  Front Pharmacol       Date:  2012-04-17       Impact factor: 5.810

7.  Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors.

Authors:  Muhammad Tariq Shehzad; Aqeel Imran; Abdul Hameed; Mariya Al Rashida; Marium Bibi; Maliha Uroos; Asnuzilawati Asari; Shafia Iftikhar; Habsah Mohamad; Muhammad Nawaz Tahir; Zahid Shafiq; Jamshed Iqbal
Journal:  RSC Adv       Date:  2021-05-11       Impact factor: 3.361

Review 8.  Nutraceuticals in prevention of cataract - An evidence based approach.

Authors:  Amandeep Kaur; Vikas Gupta; Ajay Francis Christopher; Manzoor Ahmad Malik; Parveen Bansal
Journal:  Saudi J Ophthalmol       Date:  2016-12-18

9.  Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.

Authors:  Xianwei Li; Yuanyuan Shen; Yining Lu; Jieren Yang
Journal:  Korean J Physiol Pharmacol       Date:  2015-08-20       Impact factor: 2.016

Review 10.  Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.

Authors:  Li Huang; Rongzhang He; Weihao Luo; Yuan-Shan Zhu; Jia Li; Tan Tan; Xi Zhang; Zheng Hu; Dixian Luo
Journal:  Recent Pat Anticancer Drug Discov       Date:  2016       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.